LIMX.OQXLimitless X Holdings INC
10-Q: Limitless X Holdings Reports Q3 2024 Results with Revenue Decline and Restatement
Sentiment:
Quarterly Report
Limitless X Holdings reported a decrease in revenue and a net loss for the third quarter of 2024, alongside a restatement of prior period financials.
Capital raiseThe company needs to raise additional capital to fund future operations.The company anticipates additional debt financing in the near future, but there are no current agreements or understandings regarding the form, time, or amount of such financing.
Worse than expectedThe company's product sales decreased significantly, indicating a decline in core business performance.The company's net loss, while improved from the previous year, is still substantial.The company's cash balance is very low, raising concerns about its ability to fund operations.
Summary
- Limitless X Holdings reported a net loss of $2.45 million for the nine months ended September 30, 2024, compared to a net loss of $14.43 million for the same period in 2023.
- The company's product sales decreased significantly to $3.02 million for the nine months ended September 30, 2024, from $13.89 million in the same period of 2023.
- Operating expenses decreased to $4.22 million for the nine months ended September 30, 2024, from $20.27 million in the same period of 2023, primarily due to reduced advertising, marketing, and payroll costs.
- The company restated its financial statements for the years ended December 31, 2022 and 2023, impacting the comparative periods presented.
- The company had a cash balance of $24,301 as of September 30, 2024, down from $116,100 at the end of 2023.
- The company's total liabilities were $12.24 million, while total assets were $115,800 as of September 30, 2024.
- The company has a significant accumulated deficit of approximately $37 million as of September 30, 2024.
Sentiment
Score: 3
Explanation: The document reveals significant financial challenges, including a substantial revenue decline, net losses, and a low cash balance. While there are some positive aspects, such as reduced operating expenses, the overall sentiment is negative due to the company's precarious financial position and going concern risk.
Positives
- Operating expenses decreased significantly, indicating cost-cutting measures.
- The net loss decreased substantially compared to the same period last year.
- The company converted a significant amount of Class B Preferred Stock to common stock, simplifying the capital structure.
Negatives
- Product sales experienced a significant decline, indicating a potential issue with the company's core business.
- The company's cash balance is very low, raising concerns about its ability to fund operations.
- The company has a substantial accumulated deficit, indicating a history of losses.
- The company's total liabilities significantly exceed its total assets.
Risks
- The company's ability to continue as a going concern is in doubt due to its accumulated deficit and low cash balance.
- The company needs to raise additional capital to fund future operations, and there is no guarantee that it will be able to do so.
- The company's reliance on a few suppliers poses a risk to its supply chain.
- The company has identified a material weakness in its internal controls over financial reporting.
Future Outlook
The company anticipates additional debt financing to fund operations in the near future, but there are no current agreements or understandings regarding the form, time, or amount of such financing.
Management Comments
- Management believes that the hiring of additional personnel who have the technical expertise and knowledge with the non-routine or technical issues we have encountered in the past will result in both proper recording of these transactions and a much more knowledgeable finance department as a whole.
- Management is of the opinion that legal matters will be resolved without material effect on the company's financial condition or results of operations.
Industry Context
The company operates in the health and wellness industry, which is highly competitive. The shift in marketing strategies and the decrease in sales may reflect challenges in this competitive landscape. The company's focus on performance marketing and digital services is a common trend in the industry, but the company's results suggest it is facing difficulties in executing this strategy.
Comparison to Industry Standards
- The company's significant revenue decline and net losses are concerning when compared to industry benchmarks. Many companies in the health and wellness sector are experiencing growth, while Limitless X is facing significant challenges.
- The company's reliance on a few suppliers is not uncommon in the industry, but the high concentration of purchases with one supplier (100% and 99% for the three and nine months ended September 30, 2024 and 2023, respectively) is a significant risk.
- The company's operating expenses as a percentage of revenue are very high, indicating a lack of efficiency compared to industry standards. Many companies in the sector have lower operating expenses as a percentage of revenue.
- The company's negative cash flow from operations and low cash balance are also concerning when compared to industry peers. Many companies in the sector have positive cash flow and stronger balance sheets.
Related Party Transactions
- The company has various royalty payables, notes payable to shareholders, and notes payable to related parties.
- The company incurred consulting fees to an officer and an officer of one of its affiliates.
Stakeholder Impact
- Shareholders are negatively impacted by the company's poor financial performance and going concern risk.
- Employees may be impacted by potential cost-cutting measures or layoffs.
- Customers may be impacted by potential disruptions in product availability or service quality.
- Suppliers may be impacted by the company's financial difficulties and potential inability to pay for goods or services.
- Creditors are at risk due to the company's high liabilities and low cash balance.
Next Steps
- The company plans to seek additional debt financing to fund operations.
- The company will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures and its internal controls over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2020-01-15 | Effective date of the 2020 Stock Incentive Plan. |
| 2021-03-01 | Date of an unsecured promissory note for $35,000. |
| 2021-12-01 | Date of manufacturing and distributorship license agreements with related parties. |
| 2021-12-06 | Date of a $50,000 loan from a shareholder. |
| 2022-02-11 | Date of a $150,000 loan from a shareholder. |
| 2022-05-08 | Date of a $550,000 loan from a shareholder. |
| 2022-05-10 | Date of various notes payable to related parties. |
| 2022-05-11 | Date of the Share Exchange Agreement with Limitless X, Inc. |
| 2022-05-16 | Date of a $1,100,000 loan from a shareholder. |
| 2022-05-18 | Date of a $450,000 loan from a shareholder. |
| 2022-05-20 | Completion of the LimitlessX Acquisition. |
| 2022-05-31 | Date of various notes payable to related parties. |
| 2022-06-01 | Date of a $500,000 loan from a shareholder. |
| 2022-06-09 | Date of a $15,000 note payable to a related party. |
| 2022-06-10 | Bio Lab changed its name to Limitless X Holdings Inc. |
| 2022-06-17 | Date of a loan from a shareholder. |
| 2022-06-19 | Date of a loan from a shareholder. |
| 2022-06-30 | Date of a $922,028 loan from a shareholder. |
| 2022-08-01 | Date of a loan from a shareholder. |
| 2022-08-09 | Effective date of the 2022 Stock Option Plan and 2022 Restricted Stock Plan. |
| 2022-08-25 | Date of a $290,000 loan from a shareholder. |
| 2022-11-15 | Date of a $450,000 loan from a shareholder. |
| 2023-05-01 | Date of a loan from a shareholder. |
| 2023-05-16 | Date of a $150,000 loan from a shareholder. |
| 2023-05-18 | Date of a $50,000 loan from a shareholder. |
| 2023-06-03 | Date of the Funding Commitment Agreement with Jaspreet Mathur. |
| 2023-06-05 | Date of a $150,000 loan from a shareholder. |
| 2023-06-20 | Date of a $50,000 loan from a shareholder under the Funding Commitment. |
| 2023-07-01 | Date of a loan from a shareholder. |
| 2023-07-13 | Date of a $50,000 loan from a shareholder under the Funding Commitment. |
| 2023-08-01 | Date of a $190,000 loan from a shareholder under the Funding Commitment. |
| 2023-08-07 | Date of a $50,000 loan from a shareholder under the Funding Commitment. |
| 2023-10-01 | Termination of license agreements with related parties. |
| 2023-10-23 | Issuance of Class B Preferred Stock and extinguishment of convertible debt. |
| 2024-03-12 | Date of a $20,000 loan from a related party. |
| 2024-03-15 | Date of a $419,428 loan from a related party. |
| 2024-03-27 | Date of a $100,000 loan from a related party. |
| 2024-06-30 | Date of a $44,168 loan from a related party. |
| 2024-07-31 | Date of a loan payable agreement. |
| 2024-09-30 | End of the reporting period for the quarterly report. |
| 2024-12-23 | Date of the report. |
Keywords
financial results, restatement, revenue decline, net loss, operating expenses, going concern, capital raise, product sales, internal controls, convertible stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.